Newsletter · 2026-08-10 · Ashutosh Agarwal

Lilly Laps Novo as CVS Reopens the Door to Zepbound - The Obesity-Drug Pipeline - Week of August 10, 2026

For the week of August 3 to 10, 2026, earnings week settled the sector's biggest argument: Lilly's two GLP-1 drugs did roughly $15 billion in a quarter against a Novo Nordisk guiding revenue down, and CVS reversed a year-old formulary exclusion to put Zepbound back in front of patients.

The Obesity-Drug Pipeline

Week of August 10, 2026: Lilly Laps Novo as CVS Reopens the Door to Zepbound

• Earnings week settled the biggest argument in the sector: Lilly is running away with it. Its two GLP-1 drugs did roughly $15 billion in a single quarter, Mounjaro (the diabetes version) $9.9B, up 91%; Zepbound (the weight-loss version) $4.9B, up 46%, while total company revenue hit about $23 billion and Lilly raised full-year guidance to ~$87 billion. Novo Nordisk, which invented this whole market, guided to revenue falling about 6%. Lilly now holds roughly 61% of the U.S. obesity-and-diabetes drug market to Novo's 39%. The Rundown · Elon Musk Podcast

• CVS just did a stunning U-turn and re-embraced Lilly. A year ago CVS's pharmacy arm kicked Zepbound off its formulary; this week it announced a partnership pushing Lilly's drugs hard, put the orforglipron pill on coverage now and Zepbound back on October 1, and pointed to a healthier, cheaper-to-insure member base as the reason. The Morning Market Briefing

• Retatrutide's next wave of Phase 3 data landed, and Lilly is doubling down on a controversial legal gambit. Two new trials (TRIUMPH-2 and TRIUMPH-3) showed 21–23% weight loss plus big drops in cholesterol, blood pressure and inflammation. On the earnings call, CEO David Ricks said Lilly will file retatrutide as a "biologic" in Q1, a designation that would lock out cheap copycats, with a federal appeal hearing set for September 24 in Chicago. Diabetes Dialogue · On The Pen GLP-1 News

How to read this: everything below comes from a podcast that aired in the last seven days (August 3–10, 2026). When a company executive is speaking, I label them OPERATOR/INSIDER. When it's a journalist, analyst, or commentator, I label them ANALYST/PUNDIT, an executive talking their own book is not the same as a reporter describing the field. One note up front: this was earnings week, so most of the Lilly and Novo numbers below reach us secondhand, analysts and journalists recapping the calls, not the CEOs speaking directly on these shows. The one genuine executive voice this week belonged to a would-be challenger: AstraZeneca's CFO sat for a full interview (more on that below).

What's new

1. Lilly's earnings were a blowout, and the Lilly-vs-Novo gap went from "widening" to "generational." Last week I flagged that both giants reported August 5 and that the whole thesis hung on it. Here's the verdict, as recapped on The Rundown (August 6, ANALYST/PUNDIT): Mounjaro did $9.9 billion, up 91% from a year ago, and Zepbound did $4.9 billion, up 46%, "together, these two drugs did almost $15 billion in sales in just three months." A huge slug of the growth is now international: Mounjaro's sales outside the U.S. jumped 172%, with strong demand in China, India and Brazil.

The striking part is how Lilly is doing it. As the Elon Musk Podcast (August 7, ANALYST/PUNDIT, a business-news show) laid out, the company generated "nearly $23 billion in revenue in just a single quarter," pushed net income up $1.5 billion to $7.1 billion, and raised full-year guidance by $3 billion to "up to $87 billion." But worldwide volume rose 60% while the realized price per unit fell 13%, a genuine tug-of-war between access and margin. The price drop split by geography: down just 3% in the U.S. (mostly Zepbound cash-pay cuts) but down a brutal 36% internationally, "because Mounjaro joined China's national reimbursement drug list." That's the trade every bull and bear is arguing over, in one sentence: you swap pricing power for a billion-person market.

And here's the punchline for the rivalry. On The Rundown's math, Lilly is "growing revenues by 48% while Novo's revenues are down", Novo guided to revenue declining about 6%. Lilly now controls "roughly 61% of the U.S. obesity and diabetes drug market, compared to just 39% for Novo." The host didn't hedge: "This might be a generational fumble by Novo Nordisk, because remember, they're the ones who launched this entire space with Ozempic." Lilly's stock rose nearly 5% on the print.

"Eli Lilly continues to be the weight loss juggernaut… This might be a generational fumble by Novo.", The Rundown

2. CVS reversed course and re-embraced Lilly, a real formulary win, not just noise. This is the payer story of the week, and it's a genuine flip. On The Morning Market Briefing (August 5, ANALYST/PUNDIT), the hosts explained that CVS "famously cut off Eli Lilly from its formulary this time last year, but now they're best buds." Alongside its own earnings, CVS announced a partnership to push Lilly's GLP-1s hard: transparent pricing (including rebates and insurance) on the CVS Health app, a roughly $29 one-time digital path to access, orforglipron (the pill) covered already, and Zepbound getting covered again on October 1.

Why the change of heart? Follow the money on the insurance side. CVS's medical loss ratio, the share of premium dollars it pays back out in medical claims, where lower is better for the insurer, "came in at 87%… it was almost 90 this time last year." The read: a customer base that's getting healthier on these drugs is cheaper to insure, so CVS is now incentivizing GLP-1 use rather than blocking it. For a sector where the bear case is "payers will choke off access," a giant PBM openly reversing a cut-off is a meaningful data point in the other direction.

3. Retatrutide's Phase 3 machine keeps printing, 21–23% weight loss, plus a wall of cardiovascular wins. Two fresh trials of retatrutide (Lilly's "triple-G" injection that hits three gut hormones at once) got a detailed clinical walkthrough on Diabetes Dialogue (August 4) from endocrinologists Diana Isaacs and Natalie Bellini (OPERATOR/INSIDER, practicing clinicians presenting the top-line data).

• TRIUMPH-2 (people with type 2 diabetes): up to 21% weight loss from a baseline of 106 kg; the 12 mg dose lost an average of 23 kg (about 50 lbs). A1C, the standard three-month blood-sugar average, fell 1.4 to 1.6 points versus 0.2 on placebo, and it did that off an already-low starting A1C of 7.7%, which the doctors called "really impressive." 1,000 patients, 98 centers, an 80-week trial.

• TRIUMPH-3 (people with obesity and established heart disease): 22–23% weight loss (about 53–56 lbs) at the 9 mg and 12 mg doses versus just 3% on placebo, across 1,900+ patients over 80 weeks. The cardiovascular-risk numbers were the eye-openers, at the top dose: triglycerides down 37%, non-HDL cholesterol down 17%, systolic blood pressure down 9.3 mmHg, waist circumference down 19 cm, and high-sensitivity CRP (a marker of inflammation) down 51%.

Two honest caveats the clinicians raised themselves. First, the hard heart-attack-and-stroke endpoint (three- and five-point "MACE") showed only "a trend toward improvement… not statistically significant", but 80 weeks is too short to judge that, and a proper long cardiovascular-outcomes trial is still needed. Second, tolerability is real work: in TRIUMPH-3, diarrhea hit up to 34% of patients, nausea up to 28%, vomiting up to 16%, with dose-dependent discontinuation (3.8% at 4 mg, 11% at 9 mg, 7.7% at 12 mg, versus ~5% on placebo). For context, they noted TRIUMPH-1's top dose earlier delivered 28.3% weight loss, so the menu now genuinely runs from the low-20s to near-30% depending on the drug and patient.

4. Lilly is betting the retatrutide moat on getting it classified as a "biologic", the single most important legal fight in obesity. On the earnings call, recapped by Dave Knapp (ANALYST/PUNDIT) on On The Pen GLP-1 News (August 7), CEO David Ricks "doubled down" and said Lilly plans to submit retatrutide's application as a biologic in the first quarter. Why this matters in plain terms: a biologic gets 12 years of market exclusivity instead of five, and can only be copied as a hard-to-make "biosimilar" rather than a cheap generic, so the classification would "lock out compounders" and blunt the gray market for years.

Lilly's argument rests on two technical hooks: the amino-acid count (a molecule needs 40 or more to qualify; retatrutide has 41–42, though the FDA discounts a couple it deems inactive) and an "analogous to a protein" rule. A court already sided with the FDA on the first point and called the agency's reasoning "arbitrary and capricious," sending it back, and Lilly is appealing, with the first appeal hearing September 24 in Chicago. Knapp's read is that Lilly wouldn't publicly promise investors a biologic filing unless it had "a fairly high degree of confidence," possibly informed by "open dialogue… going on behind the scenes" with the FDA. His bottom line is why a niche classification fight belongs in a hedge-fund note: whatever standard the FDA lands on "probably won't apply to retatrutide alone", it could sweep in the entire next-gen peptide field, including Viking's VK2735 and future candidates from others.

5. Lilly's oral pill Foundeo stumbled out of the gate, while Novo's Wegovy pill is a monster. The one blemish on Lilly's quarter was orforglipron, sold as Foundeo, its once-daily weight-loss pill. It did about $98 million versus the ~$103 million Wall Street expected (The Rundown). The launch is "lagging behind Novo Nordisk's weight-loss pill", and by a lot. On On The Pen, Knapp noted the Wegovy pill has done 5 million prescriptions since launch and "is absolutely blowing Foundeo out of the water… it's not even close." His theory on why: efficacy. Even patients picking pills seem to gravitate to the more potent option. Encouragingly for Lilly, Foundeo's U.S. prescription volume is now accelerating, late-July volume was "double what they saw the month prior," and prescribers jumped from about 8,000 to 36,000, and Lilly is chasing it with an aggressive 30-day sampling program and plans to launch in 40 international markets.

One telling data point on pricing power that Knapp pulled from the call: 45% of all Zepbound prescriptions, and 55% of new ones, are self-pay, people willing to pay roughly $450/month for the brand-name product. That's the confidence behind Lilly's plan to eventually sell retatrutide cash-pay through Lilly Direct.

6. Novo's most audacious pivot yet: after three years trashing "synthetic" semaglutide, it now wants to make it. This is the richest strategic story of the week, and it came through on On The Pen's August 4 episode from Dave Knapp (ANALYST/PUNDIT). For years, Novo has attacked compounded semaglutide on the grounds that compounders use chemically synthesized peptide, while Novo makes its semaglutide from a recombinant yeast process, arguing the synthetic versions carry immunogenicity, stability, potency and impurity risks. That single argument underpinned Novo's lawsuits, its push to get semaglutide onto the FDA's "demonstrably difficult to compound" list, and state-by-state legislation.

Now, per reports out of Denmark, Novo's leadership has been spending time in China, is "very close" to a Chinese manufacturing partner, and is openly exploring synthetic semaglutide itself as patents expire around the world. The logic is manufacturing math: the recombinant yeast process is labor-intensive and costly, and the Wegovy pill is brutal on supply because its high dose uses roughly 10 times the drug per day as the weekly shot to hit similar efficacy. Synthetic peptide would relieve that. Knapp's wry summary: the "audacity of a company to lambast the compounded versions for two or three years" and then quietly reach for the same technology.

The same episode surfaced two more pipeline items that matter for the competitive map:

• Pfizer is retreating from obesity. It discontinued two clinical-stage programs from its $10 billion MetSera acquisition, MET-2240 (an oral, ultra-long-acting GLP-1) and MET-0970 (an oral version of an injectable candidate), on top of previously abandoning its small-molecule pill danuglipron. It also killed PF-07976016, a GIP antagonist. Notably, Novo was the underbidder that helped drive the MetSera price to $10B, so some of the exact oral assets Novo coveted are now being scrapped.
• The "GIP paradox" is still unresolved. Tirzepatide activates the GIP receptor to produce weight loss; Amgen's MariTide blocks it and also produces weight loss. Knapp expects MariTide to reach market but flagged the catch clinicians keep seeing: heavy vomiting, which Amgen is trying to manage through slow titration. No GIP-blocker has reached market yet, so "whether blocking GIP ultimately works" is still an open question.

7. A real operator voice, AstraZeneca's CFO, says it's coming for the oral market. In the week's one genuine executive interview, AstraZeneca CFO Aradhana Sarin (OPERATOR/INSIDER) told At Barron's (August 6) that AZ has its own oral small-molecule GLP-1, "not a peptide… a small molecule oral GLP-1", with Phase 2 data coming "soon" and Phase 3 planned. Her competitive framing: "for oral medicines… really only one competitor ahead of us." AZ's angle is combinations that treat the comorbidities that ride along with obesity, hypertension, high cholesterol, rather than competing on injectable weight loss alone. She tied the GLP-1 push to AZ's ambition to reach $80 billion of revenue by 2030 (consensus, she noted, has already crept ahead to ~$82B). It's early, but it's a reminder that the "next-gen field" the bears worry about now includes a top-five global pharma aiming squarely at the pill market.

The debate

The bull case (steel-manned): This week was about as good as a bull could script. The category leader just grew revenue ~48% year-over-year, raised guidance to ~$87 billion, and pushed international volumes up triple digits, proof the demand wall the skeptics kept predicting hasn't arrived. A major PBM, CVS, publicly reversed a formulary cut and is now nudging patients toward these drugs because a healthier population is cheaper to insure, exactly the payer-alignment bulls have argued would eventually kick in. The clinical franchise keeps broadening: retatrutide now pairs ~22–23% weight loss with 37% lower triglycerides, 51% lower inflammation, and real blood-pressure drops, turning "weight-loss drug" into "cardiometabolic platform" with multiple label shots on goal. Durability is confirmed too, the SURMOUNT-643 data (below) show this is lifelong, recurring-revenue therapy. And a biologic win on retatrutide could hand Lilly 12 years of exclusivity and wall off the copycats.

The bear case (steel-manned): Read the prices, not just the volumes. Lilly grew the top line by cutting realized price 13% globally, 36% internationally, and the only way that math works is if volume keeps compounding forever. The flagship oral launch (Foundeo) missed, and got lapped 50-to-1 by Novo's pill, a reminder that being first and being biggest don't guarantee the next product works. The competitive field is thickening, not thinning: Amgen's MariTide, Viking's VK2735, and now a resourced AstraZeneca oral program are all coming, while Novo, wounded but enormous, is reaching for cheap synthetic manufacturing to defend share. On coverage, for every CVS re-embrace there's a PwC dropping weight-loss coverage and employers where "it's very difficult to make the math work." If net price keeps eroding faster than Street models assume, the multiples on both leaders are still too high.

My read (a framing, not a call): The fault line I've flagged for two weeks, volume-and-durability versus net-price-erosion, didn't resolve this week so much as it split cleanly by company. Lilly is winning the volume-and-durability argument so decisively (61% share, +91% Mounjaro, CVS coming back, retatrutide broadening) that the price erosion looks, for now, like a toll it can easily pay. Novo is losing badly enough that its defense is starting to look like imitation, chasing synthetic semaglutide it spent three years calling dangerous. The single most important variable from here isn't a number in a model; it's the September 24 biologic hearing. If Lilly gets retatrutide classified as a biologic, the entire copycat ecosystem, and the pricing math the bears rely on, changes. Watch Chicago.

Stocks in play

(This table covers the tickers discussed by name on this week's podcasts. LLY and NVO are always covered per the mandate. Roche's CT-388/CT-996, the contract manufacturers, and the pen suppliers got no airtime, see Read-throughs.)

Read-throughs

• Fast-followers (AMGN, VKTX, Roche): Half-active this week. Amgen's MariTide and Viking's VK2735 both got real mentions, but only inside other companies' stories (MariTide via the GIP-paradox discussion, VK2735 via the biologic-classification risk), not on their own merits. Roche's CT-388/CT-996 was silent again, a third straight quiet week for the Swiss program. The takeaway: the market is still treating the pipeline names as derivatives of the Lilly-Novo main event, not standalone stories.

• New pipeline entrant to watch, AstraZeneca (AZN). Not a classic "fast-follower," but a genuinely new competitive vector: a top-five pharma with an oral small-molecule GLP-1 and Phase 2 data imminent At Barron's. Also on the fringe, Talking Biotech (August 6) covered Wave Life Sciences' WVE-007, an entirely different mechanism, an RNA-interference therapy targeting the INHBE gene rather than gut hormones. Early, but a sign the "war on obesity" is broadening beyond incretins.

• Contract manufacturing / fill-finish (CTLT, LNZA, TMO): silent again, but the manufacturing theme is louder than ever. No podcast named Catalent, Lonza or Thermo Fisher. Yet the single biggest capacity story of the week was Lilly building its own capacity: an extra $4.5 billion to expand its Indiana manufacturing sites (Elon Musk Podcast), explicitly to "choke out future competitors who just can't match the production scale." Combined with Novo eyeing Chinese synthetic-peptide partners, the read is that the leaders increasingly want to own their supply chain, arguably a long-term negative for third-party fill-finish demand from these specific products.

• Pen / auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize): silent again. And the drift keeps working against them: Wegovy's pill at 5 million scripts, Foundeo's accelerating oral launch, and AstraZeneca chasing orals all point toward pills taking share from injectables over time.

• Insurers / PBMs (CVS, CI, UNH): the loudest they've been. CVS/Caremark's formulary reversal (above) is the headline, Zepbound back on October 1, orforglipron already covered, an 87% medical loss ratio as the rationale The Morning Market Briefing. Cigna's Express Scripts and UNH's Optum Rx weren't named this week.

• Employers as payers, a new, quantified data point: Bank of America. On Morning Brew Daily (August 7), CEO Brian Moynihan (OPERATOR/INSIDER, as the employer footing the bill) revealed BofA spent "about $250 million or more on GLPs… up from zero four or five years ago", roughly 13% of its $2 billion healthcare budget, and called it "the right thing to do." But the broader picture is mixed: only about one-third of global employers cover GLP-1s, just 36% cover them for both diabetes and weight loss, PwC recently stopped covering them for weight loss, and among employers with 500+ staff, 6% dropped weight-loss coverage in 2026 with 5% more planning to in 2027. Tellingly, 29% of employees say they'd switch jobs to get GLP-1 coverage, the demand is there; the corporate ROI math still isn't, for most. (Kyle Talks corroborated the BofA figure, pegging it against ~211,000 employees.)

• Real-world persistence, the durability thesis got its cleanest test yet (SURMOUNT-643). On Primary Care Update (August 3), clinicians walked through a Lilly-funded trial of reducing tirzepatide after a year. Patients who stayed on their max dose held ~22% weight loss over two years; those cut to 5 mg fell to 17% (and regained ~13 lbs); those switched to placebo held only ~10% (and regained ~28 lbs). By week 84, nearly 70% of the placebo group needed "rescue" tirzepatide, versus 25% on the low dose and just 8% on the full dose. The investment translation: this is lifelong, recurring therapy, great for the manufacturers' annuity, but it also puts the spotlight squarely on cost and adherence. (The doctors also flagged a new adverse-effect anecdote making the rounds, "Ozempic foot," a compression foot-drop after rapid weight loss.)

• Compounding / gray market: still very much alive, and the data is unflattering. A JAMA "secret-shopper" study, discussed on Diabetes Dialogue, solicited GLP-1 prescriptions from 49 telehealth websites: ~92% prescribed and ~70% mailed the drug, often "within five minutes or less," frequently with no real clinician interaction, and compounders leaned on "leading questions" (e.g., adding B12) to manufacture a "medical need" now that the shortage has ended. This is the supply that keeps capping brand pricing, and the reason Lilly's biologic gambit matters so much.

• Medtech / bariatric, and Food / QSR: quiet at the company level this week. After last week's loud dairy-protein and Intuitive Surgical read-throughs, this week offered only a passing note that surging whey-protein demand is forcing overproduction of cheese (The Morning Market Briefing). No named restaurant, medtech or bariatric company quantified a GLP-1 impact. Silence is data: the second-order consumer trade cooled off in the podcasts this week while the primary drug story dominated.

What changed vs last week

Issue #2 (August 3) was built around the Medicare BRIDGE coverage pilot, Novo's ziltovecimab heart-drug failure, retatrutide's first-wave TRIUMPH-1 data, and the biologic-classification fight. Here's the drift into this week:

• Resolved: the earnings cliffhanger, and Lilly won decisively. Last week both giants were about to report and I said the thesis hinged on it. It did. Lilly grew ~48% and took ~61% share; Novo guided revenue down ~6%. The Lilly-Novo divergence went from "widening" to what one host called a "generational fumble."

• Flipped bearish → bullish: PBM coverage. Last week the payer story leaned negative (employers retreating). This week a major PBM, CVS, publicly reversed its Lilly cut-off and is re-adding Zepbound on Oct 1, a concrete positive on the exact access axis the bears worry about.

• Extended / confirmed: retatrutide data. Last week was TRIUMPH-1 (28–30% weight loss). This week added TRIUMPH-2 (21% + strong A1C) and TRIUMPH-3 (22–23% + big cardiovascular-risk drops), and Lilly firmed up the plan to file it as a biologic in Q1, with the Sept 24 Chicago appeal reaffirmed.

• Updated: the BRIDGE pilot. New color from the call: roughly 60–70% of BRIDGE enrollees are new to GLP-1s, and ~80% are choosing injectables over pills, a mild surprise that suggests patients still equate injectables with potency.

• New this week: Novo's synthetic-semaglutide/China pivot; Pfizer scrapping its MetSera oral assets and a GIP antagonist; AstraZeneca publicly entering the oral GLP-1 race; and the SURMOUNT-643 durability data.

• Faded: Novo's ziltovecimab failure (last week's market event) got no fresh coverage; the food/CPG and medtech read-throughs that were loud last week went quiet.

• Still quiet (zero dedicated episodes): Roche CT-388/CT-996; the contract manufacturers (CTLT, LNZA, TMO) and pen suppliers (Ypsomed, Gerresheimer, Phillips Medisize) as investable names; CagriSema/UBT-251; specific state legislation (e.g., Tennessee Fair Rx Act); and clean TRx/NRx script numbers with net price per script. Unlike last week, we did get one true operator voice, AstraZeneca's CFO.